Bone Mineral Density After Transitioning From Denosumab to Alendronate.
There are few studies on subjects transitioning from denosumab to bisphosphonates. To investigate subject characteristics and changes in bone mineral density (BMD) after transitioning from denosumab to alendronate. Randomized, open-label, 2-year crossover Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531). 25 study centers in the USA and Canada. Treatment-naïve postmenopausal women with BMD T-scores ≤-2.0 to ≥-4.0. This post hoc analysis evaluated subjects randomized to denosumab 60 mg SC Q6M in year 1 followed by alendronate 70 mg QW PO in year 2. A 3% BMD threshold identified subjects who lost, maintained, or gained BMD in year 2 on alendronate. Of 126 subjects randomized to denosumab, 115 (91%) transitioned to alendronate in year 2. BMD increased by 3%-6% with denosumab in year 1 and by 0%-1% with alendronate in year 2. After transitioning to alendronate, most subjects maintained or increased BMD; 15.9%, 7.6%, and 21.7% lost BMD at the lumbar spine, total hip, and femoral neck, respectively. Few subjects fell below their pretreatment baseline BMD value; this occurred most often in those who lost BMD in year 2. Subjects who lost BMD with alendronate in year 2 also showed a greater percent change in BMD with denosumab in year 1. The BMD change in year 2 was similar regardless of baseline characteristics or adherence to oral alendronate. Alendronate can effectively maintain the BMD gains accrued after 1 year of denosumab in most subjects, regardless of baseline characteristics.